Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Initiation on Imraldi® therapy after 18th October 2018, as part of routine treatment immediately after transitioning from at least 16 weeks' treatment with originator adalimumab (Humira®)
- • Availability of at least one Baseline disease score (i.e. within 16 weeks prior or up to 6 weeks post-initiation of Imraldi®)
- • Should provide informed consent to participate in the study
- Exclusion Criteria:
- • - Unlikely to attend for regular clinic visits for the duration of study follow-up, in the opinion of the Investigator
About Biogen
Biogen is a leading biotechnology company dedicated to discovering, developing, and delivering innovative therapies for neurological and neurodegenerative diseases. With a strong focus on research and development, Biogen leverages advanced science and cutting-edge technology to address the unmet needs of patients suffering from conditions such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy. The company is committed to advancing the understanding of the underlying biology of these diseases and is actively engaged in clinical trials to evaluate new treatment options, aiming to improve patient outcomes and enhance quality of life. With a global presence and a robust pipeline of therapies, Biogen is at the forefront of innovation in the biopharmaceutical industry.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Berlin, , Germany
Hamburg, , Germany
Brugge, , Belgium
Heidelberg, , Germany
Nottingham, , United Kingdom
Milano, , Italy
Genk, , Belgium
Kortrijk, , Belgium
Liège, , Belgium
Sevilla, , Spain
Belfast, , United Kingdom
Luton, , United Kingdom
Gent, , Belgium
Magdeburg, , Germany
Munchen, , Germany
Granada, , Spain
Valladolid, , Spain
Bari, , Italy
Firenze, , Italy
Siena, , Italy
Bruxelles, , Belgium
Munich, , Germany
Oldenburg, , Germany
Turnhout, , Belgium
Dresden, , Germany
Pavia, , Italy
Ratingen, , Germany
Dublin, , Ireland
Terrassa, , Spain
Halle, , Germany
Ancona, , Italy
Modena, , Italy
Cambridge, , United Kingdom
Erfurt, , Germany
Ashford, , United Kingdom
Bath, , United Kingdom
San Giovanni Rotondo, , Italy
Herentals, , Belgium
Münster, , Germany
Mérida, , Spain
Sijsele, , Belgium
Hamm, , Germany
Foggia, , Italy
Norwich, , United Kingdom
Burghausen, , Germany
Badajoz, , Spain
Varese, , Italy
Almeria, , Spain
Elmshorn, , Germany
Kettering, , United Kingdom
Donostia, , Spain
Bruchhausen Vilsen, , Germany
Sant Joan Despi, , Spain
Sussex, , United Kingdom
Patients applied
Trial Officials
Medical Director
Study Director
Biogen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials